To ensure highest sensitivity, the ipsogen BCR-ABL1 Mbcr Kit has been optimized to detect BCR-ABL Mbcr p210 b2a2 or b3a2 transcripts and the ABL control gene using prediluted plasmid standards and primers and probe mixes (see figures Accurate detection of BCR-ABL Mbcr standards and Reliable detection of ABL plasmid standards).
The ipsogen BCR-ABL1 Mbcr Kit is a ready-to-use kit for the detection of BCR-ABL Mbcr p210 b2a2 or b3a2 fusion gene transcripts using real-time PCR. The kit is based on the amplification and detection of specific BCR-ABL Mbcr p210 b2a2 or b3a2 transcripts, relative to ABL control gene expression, in total RNA extracted from bone marrow or peripheral blood samples of acute lymphoblastic leukemia (ALL) or chronic myeloid leukemia (CML) patients previously diagnosed with a BCR-ABL Mbcr fusion gene event. The kit provides high levels of specificity, sensitivity, and reproducibility. The ipsogen BCR-ABL1 Mbcr Kit provides 5 standard dilutions for Mbcr and 3 standard dilutions for ABL. Use of the standards enables accurate quantification of transcripts. Specific primers and probe mixes and standard serial dilutions of control and fusion DNA are provided for the quantification of the BCR-ABL1 Mbcr genes and the ABL control gene according to Europe Against Cancer (EAC) recommendations (see figures BCR-ABL Mbcr fusion gene transcript and ABL control gene transcript).